Ionis Pharmaceuticals Inc (NASDAQ:IONS) Director Joseph Klein III sold 3,000 shares of Ionis Pharmaceuticals stock in a transaction dated Friday, December 15th. The shares were sold at an average price of $51.69, for a total value of $155,070.00. Following the transaction, the director now directly owns 12,939 shares in the company, valued at $668,816.91. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Joseph Klein III also recently made the following trade(s):

  • On Thursday, November 30th, Joseph Klein III sold 3,000 shares of Ionis Pharmaceuticals stock. The shares were sold at an average price of $53.55, for a total value of $160,650.00.
  • On Wednesday, November 15th, Joseph Klein III sold 2,250 shares of Ionis Pharmaceuticals stock. The shares were sold at an average price of $53.56, for a total value of $120,510.00.
  • On Monday, November 13th, Joseph Klein III sold 3,000 shares of Ionis Pharmaceuticals stock. The shares were sold at an average price of $55.39, for a total value of $166,170.00.

Shares of Ionis Pharmaceuticals Inc (NASDAQ:IONS) traded down $0.20 during trading hours on Thursday, reaching $50.73. The company had a trading volume of 691,600 shares, compared to its average volume of 1,436,149. Ionis Pharmaceuticals Inc has a 12 month low of $37.26 and a 12 month high of $65.51. The firm has a market cap of $6,355.83, a price-to-earnings ratio of 339.53 and a beta of 2.85. The company has a quick ratio of 6.21, a current ratio of 6.25 and a debt-to-equity ratio of 1.50.

A number of large investors have recently made changes to their positions in the stock. Vanguard Group Inc. increased its holdings in shares of Ionis Pharmaceuticals by 4.4% in the second quarter. Vanguard Group Inc. now owns 9,855,160 shares of the company’s stock valued at $501,332,000 after purchasing an additional 417,364 shares during the period. American Century Companies Inc. boosted its position in shares of Ionis Pharmaceuticals by 33.0% during the third quarter. American Century Companies Inc. now owns 1,144,526 shares of the company’s stock worth $58,027,000 after buying an additional 284,266 shares during the period. First Trust Advisors LP boosted its position in shares of Ionis Pharmaceuticals by 40.2% during the third quarter. First Trust Advisors LP now owns 982,344 shares of the company’s stock worth $49,805,000 after buying an additional 281,733 shares during the period. BlackRock Inc. boosted its position in shares of Ionis Pharmaceuticals by 4.0% during the second quarter. BlackRock Inc. now owns 6,823,987 shares of the company’s stock worth $347,135,000 after buying an additional 264,179 shares during the period. Finally, Aviva PLC purchased a new position in shares of Ionis Pharmaceuticals during the second quarter worth $10,187,000. 91.40% of the stock is currently owned by institutional investors.

A number of research analysts have recently weighed in on IONS shares. Stifel Nicolaus reaffirmed a “hold” rating and set a $50.00 price objective on shares of Ionis Pharmaceuticals in a research report on Friday, October 13th. Zacks Investment Research raised Ionis Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $62.00 target price on the stock in a research note on Friday, October 27th. Morgan Stanley lifted their target price on Ionis Pharmaceuticals from $45.00 to $49.00 and gave the company an “equal weight” rating in a research note on Wednesday, November 8th. BMO Capital Markets lifted their target price on Ionis Pharmaceuticals from $64.00 to $65.00 and gave the company an “outperform” rating in a research note on Wednesday, November 8th. Finally, Barclays initiated coverage on Ionis Pharmaceuticals in a research note on Wednesday, September 6th. They issued an “equal weight” rating and a $55.00 price objective on the stock. Three investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and seven have given a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $50.31.

COPYRIGHT VIOLATION WARNING: This story was originally posted by Watch List News and is owned by of Watch List News. If you are viewing this story on another domain, it was stolen and republished in violation of US and international trademark and copyright law. The original version of this story can be accessed at https://www.watchlistnews.com/joseph-klein-iii-sells-3000-shares-of-ionis-pharmaceuticals-inc-ions-stock/1776271.html.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.

Insider Buying and Selling by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.